Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey)
Senegal introduced the infant hepatitis B virus (HBV) vaccination in 2004 and recently committed to eliminating hepatitis B by 2030. Updated epidemiological data are needed to provide information on the progress being made and to develop new interventions. We estimated the prevalence of hepatitis B...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2022-05-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.1879 |
| _version_ | 1827881419496488960 |
|---|---|
| author | Lauren Périères Aldiouma Diallo Fabienne Marcellin Marie Libérée Nishimwe El Hadji Ba Marion Coste Gora Lo Philippe Halfon Coumba Touré Kane Gwenaëlle Maradan Patrizia Carrieri Assane Diouf Yusuke Shimakawa Cheikh Sokhna Sylvie Boyer ANRS 12356 AmBASS Survey Study Group |
| author_facet | Lauren Périères Aldiouma Diallo Fabienne Marcellin Marie Libérée Nishimwe El Hadji Ba Marion Coste Gora Lo Philippe Halfon Coumba Touré Kane Gwenaëlle Maradan Patrizia Carrieri Assane Diouf Yusuke Shimakawa Cheikh Sokhna Sylvie Boyer ANRS 12356 AmBASS Survey Study Group |
| author_sort | Lauren Périères |
| collection | DOAJ |
| description | Senegal introduced the infant hepatitis B virus (HBV) vaccination in 2004 and recently committed to eliminating hepatitis B by 2030. Updated epidemiological data are needed to provide information on the progress being made and to develop new interventions. We estimated the prevalence of hepatitis B surface antigen (HBsAg) in children and adults living in rural Senegal and assessed hepatitis B treatment eligibility. A cross‐sectional population‐based serosurvey of HBsAg was conducted in 2018‐2019 in a large sample (n = 3,118) of residents living in the Niakhar area (Fatick region, Senegal). Individuals positive for HBsAg subsequently underwent clinical and biological assessments. Data were weighted for age and sex and calibrated to be representative of the area’s population. Among the 3,118 participants, 206 were HBsAg positive (prevalence, 6.9%; 95% confidence interval [CI], 5.6‐8.1). Prevalence varied markedly according to age group in individuals aged 0‐4, 5‐14, 15‐34, and ≥35 years as follows: 0.0% (95% CI, 0.00‐0.01); 1.5% (95% CI, 0.0‐2.3); 12.4% (95% CI, 9.1‐15.6); and 8.8% (95% CI, 6.1‐11.5), respectively. Of those subsequently assessed, 50.9% (95% CI, 41.8‐60.0) had active HBV infection; 4 (2.9%; 95% CI, 0.9‐9.4) were eligible for hepatitis B treatment. Conclusion: In this first population‐based serosurvey targeting children and adults in rural Senegal, HBsAg prevalence was very low in the former, meeting the World Health Organization’s (WHO) < 1% HBsAg 2020 target; however, it was high in young adults (15‐34 years old) born before the HBV vaccine was introduced in 2004. To reach national and WHO hepatitis elimination goals, general population testing (particularly for adolescents and young adults), care, and treatment scale‐up need to be implemented. |
| first_indexed | 2024-03-12T18:38:16Z |
| format | Article |
| id | doaj.art-d5543feed2d34204a13f63f52a511d99 |
| institution | Directory Open Access Journal |
| issn | 2471-254X |
| language | English |
| last_indexed | 2024-03-12T18:38:16Z |
| publishDate | 2022-05-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj.art-d5543feed2d34204a13f63f52a511d992023-08-02T07:55:56ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2022-05-01651005101510.1002/hep4.1879Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey)Lauren Périères0Aldiouma Diallo1Fabienne Marcellin2Marie Libérée Nishimwe3El Hadji Ba4Marion Coste5Gora Lo6Philippe Halfon7Coumba Touré Kane8Gwenaëlle Maradan9Patrizia Carrieri10Assane Diouf11Yusuke Shimakawa12Cheikh Sokhna13Sylvie Boyer14ANRS 12356 AmBASS Survey Study GroupVecteurs–Infections Tropicales et Méditerranéennes (VITROME)Campus Institut de Recherche pour le Développement (IRD)‐Universite Cheikh Anta Diop Dakar SenegalVecteurs–Infections Tropicales et Méditerranéennes (VITROME)Campus Institut de Recherche pour le Développement (IRD)‐Universite Cheikh Anta Diop Dakar SenegalInstitut National de la Santé et de la Recherche MédicaleIRDSciences Economiques and Sociales de la Santé and Traitement de l’Information MédicaleInstitut des Sciences de la Santé Publique ‐ ISSPAMAix‐Marseille University Marseille FranceInstitut National de la Santé et de la Recherche MédicaleIRDSciences Economiques and Sociales de la Santé and Traitement de l’Information MédicaleInstitut des Sciences de la Santé Publique ‐ ISSPAMAix‐Marseille University Marseille FranceVecteurs–Infections Tropicales et Méditerranéennes (VITROME)Campus Institut de Recherche pour le Développement (IRD)‐Universite Cheikh Anta Diop Dakar SenegalInstitut National de la Santé et de la Recherche MédicaleIRDSciences Economiques and Sociales de la Santé and Traitement de l’Information MédicaleInstitut des Sciences de la Santé Publique ‐ ISSPAMAix‐Marseille University Marseille FranceInstitut de Recherche en Santé de Surveillance Epidémiologique et de Formation Dakar SenegalLaboratoire Alphabio Hôpital Européen Marseille FranceInstitut de Recherche en Santé de Surveillance Epidémiologique et de Formation Dakar SenegalInstitut National de la Santé et de la Recherche MédicaleIRDSciences Economiques and Sociales de la Santé and Traitement de l’Information MédicaleInstitut des Sciences de la Santé Publique ‐ ISSPAMAix‐Marseille University Marseille FranceInstitut National de la Santé et de la Recherche MédicaleIRDSciences Economiques and Sociales de la Santé and Traitement de l’Information MédicaleInstitut des Sciences de la Santé Publique ‐ ISSPAMAix‐Marseille University Marseille FranceVecteurs–Infections Tropicales et Méditerranéennes (VITROME)Campus Institut de Recherche pour le Développement (IRD)‐Universite Cheikh Anta Diop Dakar SenegalUnité d'Épidémiologie des Maladies Émergentes Institut Pasteur Paris FranceIRDService de santé des arméesVITROMEAix‐Marseille University Marseille FranceInstitut National de la Santé et de la Recherche MédicaleIRDSciences Economiques and Sociales de la Santé and Traitement de l’Information MédicaleInstitut des Sciences de la Santé Publique ‐ ISSPAMAix‐Marseille University Marseille FranceSenegal introduced the infant hepatitis B virus (HBV) vaccination in 2004 and recently committed to eliminating hepatitis B by 2030. Updated epidemiological data are needed to provide information on the progress being made and to develop new interventions. We estimated the prevalence of hepatitis B surface antigen (HBsAg) in children and adults living in rural Senegal and assessed hepatitis B treatment eligibility. A cross‐sectional population‐based serosurvey of HBsAg was conducted in 2018‐2019 in a large sample (n = 3,118) of residents living in the Niakhar area (Fatick region, Senegal). Individuals positive for HBsAg subsequently underwent clinical and biological assessments. Data were weighted for age and sex and calibrated to be representative of the area’s population. Among the 3,118 participants, 206 were HBsAg positive (prevalence, 6.9%; 95% confidence interval [CI], 5.6‐8.1). Prevalence varied markedly according to age group in individuals aged 0‐4, 5‐14, 15‐34, and ≥35 years as follows: 0.0% (95% CI, 0.00‐0.01); 1.5% (95% CI, 0.0‐2.3); 12.4% (95% CI, 9.1‐15.6); and 8.8% (95% CI, 6.1‐11.5), respectively. Of those subsequently assessed, 50.9% (95% CI, 41.8‐60.0) had active HBV infection; 4 (2.9%; 95% CI, 0.9‐9.4) were eligible for hepatitis B treatment. Conclusion: In this first population‐based serosurvey targeting children and adults in rural Senegal, HBsAg prevalence was very low in the former, meeting the World Health Organization’s (WHO) < 1% HBsAg 2020 target; however, it was high in young adults (15‐34 years old) born before the HBV vaccine was introduced in 2004. To reach national and WHO hepatitis elimination goals, general population testing (particularly for adolescents and young adults), care, and treatment scale‐up need to be implemented.https://doi.org/10.1002/hep4.1879 |
| spellingShingle | Lauren Périères Aldiouma Diallo Fabienne Marcellin Marie Libérée Nishimwe El Hadji Ba Marion Coste Gora Lo Philippe Halfon Coumba Touré Kane Gwenaëlle Maradan Patrizia Carrieri Assane Diouf Yusuke Shimakawa Cheikh Sokhna Sylvie Boyer ANRS 12356 AmBASS Survey Study Group Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey) Hepatology Communications |
| title | Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey) |
| title_full | Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey) |
| title_fullStr | Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey) |
| title_full_unstemmed | Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey) |
| title_short | Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey) |
| title_sort | hepatitis b in senegal a successful infant vaccination program but urgent need to scale up screening and treatment anrs 12356 ambass survey |
| url | https://doi.org/10.1002/hep4.1879 |
| work_keys_str_mv | AT laurenperieres hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT aldioumadiallo hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT fabiennemarcellin hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT marielibereenishimwe hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT elhadjiba hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT marioncoste hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT goralo hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT philippehalfon hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT coumbatourekane hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT gwenaellemaradan hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT patriziacarrieri hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT assanediouf hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT yusukeshimakawa hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT cheikhsokhna hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT sylvieboyer hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey AT anrs12356ambasssurveystudygroup hepatitisbinsenegalasuccessfulinfantvaccinationprogrambuturgentneedtoscaleupscreeningandtreatmentanrs12356ambasssurvey |